CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD7 靶向通用型 CAR-T 细胞联合供者造血干细胞实现稳定植入及无移植物抗宿主病、无复发生存：一例病例报告提示
英文原题：Stable engraftment, as well as graft versus host disease-free and relapse-free survival brought by the combination of CD7 targeted universal chimeric antigen receptor-T, and donor hemopoietic stem cells: Indication of a case report.
查看英文原题
Stable engraftment, as well as graft versus host disease-free and relapse-free survival brought by the combination of CD7 targeted universal chimeric antigen receptor-T, and donor hemopoietic stem cells: Indication of a case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向 CD7 的 CAR-T 已显示治疗 T 细胞恶性肿瘤的潜力，但尚无研究报道其预防异基因造血干细胞移植（allo-HSCT）后移植物抗宿主病（GVHD）的作用。本文报告一个特殊病例：一名难治性 T 细胞急性淋巴细胞白血病（T-ALL）男孩接受通用型 CD7 靶向 CAR-T（CD7 UCAR-T）治疗及亲本来源外周血干细胞（PBSC）移植。患者达到完全缓解，供者细胞完全植入。随后 4 个月随访期间，患者未接受任何免疫抑制治疗，也未见 GVHD 迹象。本病例初步显示 CD7 UCAR-T 可能具有预防 GVHD 的潜力。
展开英文摘要原文
CD7 targeted CAR-T has demonstrated potential in the treatment of T cell malignancies but no study has been reported about its potential in the prophylaxis of GVHD in allo-HSCT.
Here we reported a special case that a boy diagnosed with refractory acute T lymphoblastic leukemia (T-ALL) was treated with universal CD7 targeted CAR-T (CD7 UCAR-T) and parent-derived peripheral blood stem cells (PBSCs). Complete remission and full engraftment of donor was observed. In the later four months of follow-up, in the absence of any immunodepression treatment, no signs of GVHD were observed. This case initially demonstrates the potential of CD7 UCAR-T in the prophylaxis of GVHD.
论文信息
- 作者
- Li S、Yuan Z、Liu L、Li Y、Luo L、Peng L、Xu M、Yin P
- 单位
- Department of Hematology 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China Kunming China.China
- 期刊
- EJHaem2024 Jun
- 原文标识
- PubMed 38895056 · DOI 10.1002/jha2.914
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →